Horizon Pharmaceutical Inactive 10-Q2013 Q2 Quarterly report

Filed: 9 Aug 13, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: absorption, ADO, afoul, aggressive, Alzheimer, American, Annex, antioxidant, Article, aspect, assert, ATRA, attached, automatic, autosomal, axonal, ballooning, basal, benign, biopsy, breakthrough, buyer, cancel, cancellation, carcinoma, cellular, cerebral, chain, chance, child, CHMP, chorea, Clinique, cognitive, complementary, composed, confirmed, consequential, cortex, cortical, counted, cysteine, de, dementia, differentiation, diligence, dioxygenase, dissolution, dominant, Dossier, excessive, extracellular, family, fat, fibrotic, fraud, fungible, ganglia, Gastroenterology, glycine, gradually, hallmark, hard, HCC, hepatic, hepatocellular, hepatocyte, histopathology, Htt, huntingtin, hybrid, hypertriglyceridemia, Iceland, ideal, imaging, IMPD, impractical, infancy, inflammation, injury, irreversible, jerky, Liechtenstein, living, lobular, mandate, mandated, markedly, master, mental, mercaptamine, misdiagnosed, Motor, movement, mutant, mutation, NAFL, neuropsychiatric, Neurotropic, nil, Nonproprietary, Norway, Obama, officially, onset, optimal, pathophysiology, percentile, persuasive, physical, play, premature, prerequisite, Programme, prominent, proven, Proxy, psychiatric, ramping, ratification, ratified, reach, reaching, recast, Recherche, refund, relief, remotely, replacement, reserve, reserved, retail, retrospective, role, run, scar, scrapped, screened, screening, secreted, seller, sequestration, serum, shareholder, shipment, shipped, shipping, simple, space, striatal, Strict, susceptible, symptomatic, Taxpayer, temporary, thiol, thrive, tracking, transaminase, triad, trillion, triplet, unacknowledged, underdeveloped, underdiagnosed, Union, Vermont, week, western, whichever

Removed: APB, assigned, drawn, entitled, initially, mature, modified, nominal, par, recording, recovery, reference, retroactively, submitted, vest

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Horizon Pharmaceutical similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 10.5

Amendment to Manufacturing Services Agreement

between Patheon Pharmaceuticals Inc., and Raptor Therapeutics, Inc.

Background: Patheon Pharmaceuticals Inc., ("Patheon") and Raptor Therapeutics, Inc., ("Raptor") entered into a Manufacturing Services Agreement dated November 15, 2010 (the "Agreement"). Patheon and Raptor wish to amend the Agreement to revise Schedule B.

NOW THEREFORE in consideration of the premises hereof and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by the parties, the parties agree to amend the Agreement as follows:

1. Amendment to Agreement:

Schedule B to the Agreement is deleted in its entirety and is replaced with a new Schedule B as attached to this Amendment.

2.	No Other Modifications. The "Background" section of this document is incorporated into the Amendment. Except as modified by this Amendment, the terms and conditions of the Agreement remain unchanged.

IN WITNESS WHEREOF, the parties have caused this Amendment to be duly executed by their authorized representatives, effective as of April 5, 2012.

RAPTOR THERAPEUTICS, INC.	PATHEON PHARMACEUTICALS INC.

By: /s/ Thomas E. Daley	By: /s/ Francis P. McCune
Name: Thomas E. Daley	Name: Francis P. McCune
Title: President	Title: Secretary
	APPROVED BY LEGAL
		FPM	4-13-12
		Initials	Date

| SV\1167726.1||

SCHEDULE B

(as revised by the Amendment to the Agreement effective April 5 2012)

MINIMUM RUN QUANTITY, ANNUAL VOLUME, AND PRICE

[****]

| SV\1167726.1||